Correspondingly, EGFR inhibition could substantially improve insulin sensitivity by reducing inflammation in insulin target tissue in obese mice, where EGFR inhibition enhances IRS-1 signaling, providing a potential therapeutic target for insulin resistance (Fig. 1). Here, EGFR is linked to Insulin resistance.